Manufacturer of Controlled Substances; Notice of Registration, 70986-70987 [E6-20689]
Download as PDF
<![CDATA[
70986
Federal Register / Vol. 71, No. 235 / Thursday, December 7, 2006 / Notices
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Importer of Controlled Substances;
Notice of Registration
By Notice dated July 19, 2006, and
published in the Federal Register on
July 26, 2006, (71 FR 42417), Lin Zhi
International, Inc., 687 North Pastoria
Avenue, Sunnyvale, California 94085,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Schedule
Tetrahydrocannabinols (7370) .....
3,4–Methylenedioxy-methamphetamine (7405).
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (9273)
Morphine (9300) ...........................
I
I
II
II
II
II
II
II
sroberts on PROD1PC70 with NOTICES
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20693 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
17:29 Dec 06, 2006
Jkt 211001
Drug
By Notice dated July 10, 2006 and
published in the Federal Register on
July 24, 2006, (71 FR 41837–41838),
Lipomed Inc., One Broadway,
Cambridge, Massachusetts 02142, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule I and II:
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Methaqualone (2565) ...................
Gamma
hydroxybutyric
acid
(2010).
Lysergic acid diethylamide (7315),
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7438).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (7405).
4-Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Sufentanil (9740) ..........................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Lipomed Inc. to import the basic classes
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Lipomed Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20745 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 25, 2006, and
published in the Federal Register on
July 31, 2006, (71 FR 43211), MGI
Pharma, 6611 Tributary Street,
Baltimore, Maryland 21224, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
E:\FR\FM\07DEN1.SGM
07DEN1
70987
Federal Register / Vol. 71, No. 235 / Thursday, December 7, 2006 / Notices
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
cocaine derivative to be used in
domestic and foreign clinical research
studies.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of MGI
Pharma to manufacture the listed basic
class of controlled substance is
consistent with the public interest at
this time. DEA has investigated MGI
Pharma to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20689 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 26, 2006, and
published in the Federal Register on
August 2, 2006, (71 FR 43814), Orasure
Technologies, Inc., Lehigh University,
Seeley G. Mudd-Building 6, Bethlehem,
Pennsylvania 18015, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
sroberts on PROD1PC70 with NOTICES
Schedule
Lysergic acid diethylamide (LSD)
(7315).
4–Methoxyamphetamine (7411) ...
Normorphine (9313) .....................
Tetrahydrocannabinols
(THC)
(7370).
Alphamethadol (9605) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Cocaine (9041) .............................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
VerDate Aug<31>2005
17:29 Dec 06, 2006
I
I
I
I
I
II
II
II
II
II
II
Jkt 211001
Schedule
Morphine (9300) ...........................
Oxycodone (9143) ........................
Meperidine (9230) ........................
Methadone (9250) ........................
Oxymorphone (9652) ...................
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
to manufacture controlled substance
derivatives. These derivatives will be
used in diagnostic products created
specifically for internal use only.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Orasure Technologies, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Orasure Technologies, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20744 Filed 12–6–06; 8:45 am]
DEPARTMENT OF JUSTICE
Drug
Drug
BILLING CODE 4410–09–P
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 5, 2007.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20698 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated August 7, 2006 and
published in the Federal Register on
August 15, 2006, (71 FR 46922), Penick
Corporation, 33 Industrial Park Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule II:
Drug
DEPARTMENT OF JUSTICE
Schedule
Manufacturer of Controlled
Substances; Notice of Application
Coca Leaves (9040) .....................
Raw Opium (9600) .......................
Poppy Straw (9650) .....................
Concentrate of Poppy Straw
(9670).
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 20,
2006, Organix Inc., 240 Salem Street,
Woburn, Massachusetts 01801, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Cocaine (9041), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture a
chemical that is a derivative of cocaine
that will be sold to their customer for
research purposes.
Any other such applicant and any
person who is presently registered with
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Penick Corporation to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Penick
Corporation to ensure that the
company’s registration is consistent
Drug Enforcement Administration
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
E:\FR\FM\07DEN1.SGM
07DEN1
II
II
II
II
]]>Agencies
[Federal Register Volume 71, Number 235 (Thursday, December 7, 2006)]
[Notices]
[Pages 70986-70987]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-20689]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated July 25, 2006, and published in the Federal
Register on July 31, 2006, (71 FR 43211), MGI Pharma, 6611 Tributary
Street, Baltimore, Maryland 21224, made application to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Cocaine (9041),
[[Page 70987]]
a basic class of controlled substance listed in schedule II.
The company plans to manufacture a cocaine derivative to be used in
domestic and foreign clinical research studies.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
MGI Pharma to manufacture the listed basic class of controlled
substance is consistent with the public interest at this time. DEA has
investigated MGI Pharma to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with State and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic class of controlled substance listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-20689 Filed 12-6-06; 8:45 am]
BILLING CODE 4410-09-P
